Answers are grounded in this paper and cite their sources.
Demonstrates synthesis of tricyclic benzo[1,3]oxazinyloxazolidinones that inhibit coagulation factor Xa, identifying compound 16b as a promising candidate for antithrombotic therapies.
The coagulation enzyme factor Xa (FXa) is a valuable target for developing anticoagulants to treat thrombotic diseases. In this work, we designed and synthesized a series of conformationally restricted compounds containing the benzo[1,3]oxazinyloxazolidinone scaffold. The target compounds were synthesized by 11 steps reaction. The preliminary SAR showed that on the phenyl ring of benzo[1,3]oxazinyloxazolidinone, lactam replacements at the 6-position were favorable for FXa inhibition. Compound 16b showed good FXa inhibitory activity with an IC50 of 0.43 μM. The results indicate that benzo[1,3]oxazinyloxazolidinone is a promising scaffold for developing FXa inhibitors as antithrombotic agents.
No takes yet. Share an insight, caveat, or question.
Lu et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: